NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00006343,STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia,https://clinicaltrials.gov/study/NCT00006343,,COMPLETED,"RATIONALE: Biological therapies such as interferon-alfa and STI571 may interfere with the growth of cancer cells. It is not yet known if STI571 is more effective than interferon alfa plus cytarabine for chronic myelogenous leukemia.

PURPOSE: Randomized phase III trial to compare the effectiveness of STI571 with that of interferon alfa plus cytarabine in treating patients who have newly diagnosed chronic myelogenous leukemia.",NO,Leukemia,BIOLOGICAL: recombinant interferon alfa|DRUG: cytarabine|DRUG: imatinib mesylate,,,,Novartis,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE3,,INDUSTRY,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,CDR0000068089|NOVARTIS-CSTI5710106|FHCRC-1556.00,2000-06,2007-03,2007-03,2004-05-26,,2013-01-03,"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, 07936, United States",
